Has Karen Albritton received payments from drug or device companies?

Yes. Drug and device makers reported $31,002 in general payments to Karen Albritton across 47 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Karen Albritton did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Karen Albritton come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Karen Albritton

Pediatric Hematology-Oncology · Fort Worth, TXNPI 1982664074

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,676 of the $31,002 with a category attached, or 89.3%. Jazz Pharmaceuticals Inc. accounts for 97.9% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $30,127, more than ten times the $117 reported in 2019. Among pediatric hematology-oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,002in general payments, 2019–2025

Across 47 payments — averaging $659.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$30K
Servier Pharmaceuticals LLC$301
Tempus AI, Inc$163
AstraZeneca$69
Pfizer$35
Foundation Medicine, Inc.$30
plus $59 from 3 others

$213,355in research payments, 2019–2025

Across 73 payments — averaging $2922.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$105K
AbbVie$88K
Novartis$20K
Eli Lilly$476

What the payments were for

Speaking & faculty fees$27,67689%
Travel & lodging$1,9626%
Food & beverage$1,3644%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	27	$30,344
Servier Pharmaceuticals LLC	5	$301
Tempus AI, Inc	5	$163
AstraZeneca	4	$69
Pfizer	2	$35
Foundation Medicine, Inc.	1	$30
Syndax Pharmaceuticals, Inc.	1	$24
Seagen Inc.	1	$18
Adaptive Biotechnologies Corporation	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RYLAZE$29,815
ONCASPAR$117
ASPARLAS$109

How this compares

$31,002 in reported general payments places this provider in the 90th percentile of 235 pediatric hematology-oncology providers in Texas.

See all pediatric hematology-oncology providers in Texas →

Other pediatric hematology-oncology in Fort Worth

Anish RayFort Worth$164K
Kelly VallanceFort Worth$82K
Timothy McCavitFort Worth$55K
Donald BeamFort Worth$3K
Stanton GoldmanDallas$234K
Vivek SubbiahHouston$194K
Maurizio GhisoliDallas$174K
Joel WeinthalDallas$161K
Prasad MathewEl Paso$153K
Vinod Gidvani-DiazSan Antonio$101K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →